Vesilute vs Vesugen
Moderate Research vs Moderate Research
compatible Different targets - Vesugen for vascular, Vesilute for bladder/prostate. Can be combined.
Molecular Data
Vesilute Vesugen
Weight 262 Da 390 Da
Half-life Not established Not established
Chain 2 amino acids 3 amino acids
Type Dipeptide bioregulator Tripeptide bioregulator
Key Benefits
Vesilute
01 Supports bladder and urinary tract function
02 May improve prostate health in men
03 Regulates smooth muscle function
04 Enhances pelvic tissue blood flow
05 Supports cellular regeneration
06 Part of comprehensive Khavinson bioregulator protocols
07 Well-tolerated in research
08 Oral bioavailability as small dipeptide
Vesugen
01 Protects vascular system from aging effects
02 Limits atherosclerosis development
03 Decreases endothelial cell dysfunction
04 Activates SIRT1 anti-aging pathway
05 Enhances stem cell proliferation
06 Reduces cellular senescence markers
07 Reverses SASP phenotype
08 Works synergistically with Cardiogen
Dosing Protocols
Vesilute
10-20 mg per day / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Standard protocol 10-20 mg Daily for 10-20 days
Maintenance 20 mg 2-3 cycles yearly
Vesugen
10-20 mg per day (oral capsules) or 10 mg (injectable) / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Research protocol 10 mg Daily for 10 days
Side Effects
Vesilute
Generally well-tolerated
Injection site reactions (mild, if injectable)
Minimal reported side effects
Vesugen
Generally well-tolerated
Minimal side effects reported
Contraindications
Known hypersensitivity to peptide components
Active urinary tract infection (treat first)
Pregnancy or breastfeeding
Prostate cancer (consult physician)
Active cardiovascular emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
Vesilute Vesugen
Status Moderate Research Moderate Research
References 3 studies 3 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.